David A. Siegel Tg Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 225,500 shares of TGTX stock, worth $7.02 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
225,500
Previous 166,100
35.76%
Holding current value
$7.02 Million
Previous $2.95 Million
78.54%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding TGTX
# of Institutions
340Shares Held
88.5MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$479 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$355 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$283 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$112 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$99.8 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.53B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...